Tolga Tanguler Purchases Shares in Lexeo Therapeutics
Tolga Tanguler acquired 35,000 shares of Lexeo Therapeutics on June 25, 2026.
Key Points
- Tolga Tanguler bought 35,000 shares of Lexeo Therapeutics, Inc. (LXEO) on June 25, 2026, without a specified purchase price.
- Shares of Lexeo Therapeutics traded near $4.75 on Tuesday, with a market cap of approximately $373 million and a beta of 1.389.
- JP Morgan maintained a 'buy' rating for Lexeo, with a price target of $9.00 as of June 25, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Tolga Tanguler recently purchased 35,000 shares of Lexeo Therapeutics, Inc. (NasdaqGM: LXEO) on June 25, 2026. The transaction was not planned, and no purchase price was specified.
Insider Buying and Selling at Lexeo Therapeutics, Inc.
Several insiders, including Tolga Tanguler, bought 35,000 shares each of Lexeo Therapeutics on June 25, 2026. These transactions were not made under any prearranged plans.
Other Institutional Activity in Lexeo Therapeutics
PARADIGM BIOCAPITAL ADVISORS LP increased its stake by 1,420,936 shares, ending with 6,184,134 shares worth about $35.5 million. BLACKROCK, INC. added 203,308 shares, bringing its total to 5,110,871 shares valued at approximately $29.3 million. AFFINITY ASSET ADVISORS, LLC boosted its holdings by 1,850,211 shares, reaching a total of 5,050,211 shares valued at $28.99 million. Meanwhile, JANUS HENDERSON GROUP PLC reduced its position by 533,206 shares, now holding 4,976,429 shares worth $28.51 million.
Lexeo Therapeutics, Inc. Stock Down 2.3%
Shares of Lexeo Therapeutics traded near $4.75 on Tuesday. The company, with a market cap of around $373 million, operates in the biotechnology sector. Lexeo's stock has a 52-week low of $3.60 and a high of $10.99. Its 50-day moving average is $5.27, while the 200-day moving average stands at $7.14. The company has a forward P/E ratio that is not meaningful as it is currently not profitable.
$LXEO stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 25, 2026, JP Morgan maintained its 'buy' rating for Lexeo Therapeutics with a price target of $9.00. Chardan Capital also maintained a 'buy' rating with a target of $17.00 on May 11, 2026. The consensus among analysts is a 'strong buy', with an average target price of $20.60 based on 10 opinions.
About Lexeo Therapeutics
Lexeo Therapeutics, Inc. is a biotechnology company based in New York, NY. Founded in 2017, it focuses on developing gene therapies for hereditary and acquired diseases. Its pipeline includes treatments for conditions like Friedreich ataxia cardiomyopathy and Alzheimer's disease. The company collaborates with Cornell University on several projects and has a dedicated team of 59 employees led by CEO Mr. R. Nolan Townsend.
Bottom Line
Tolga Tanguler's recent share purchase in Lexeo Therapeutics highlights insider confidence in the company's prospects. Investors often watch insider transactions for potential signals, though it's important to remember these are backward-looking reports. Lexeo's stock remains a focus for analysts, who currently rate it as a 'strong buy'.
Get Lexeo Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $LXEO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.